AMAX-126

AMAX-126 is an orally administered, multi-targeting antineoplastic drug candidate developed by Aveta Biomics for the treatment of glioblastoma and other high-grade gliomas. It is classified as a new molecular entity and is currently in Phase 1/2 clinical trials for glioblastoma. The precise mechanism of action has not been fully defined or disclosed publicly, but it is described as invoking a novel mechanism to treat aggressive brain cancers with promising early preclinical results. The drug aims to address resistance mechanisms seen with current therapies such as bevacizumab and may also act through microglia reprogramming from an M2 (tumor-supportive) to M1 (tumoricidal) state[1][3]. Aveta Biomics holds worldwide rights to the compound[1][2].